According to Isomorphic Labs (@IsomorphicLabs), the company has entered into a strategic partnership with Johnson & Johnson Innovation (@JNJInnovation) to leverage Isomorphic's AI drug design engine alongside J&J’s robust drug development capabilities. This collaboration aims to address historically difficult-to-drug disease targets by integrating cross-modality and multi-target research strategies. The partnership is expected to accelerate the path to new medicines and represents a significant advancement in digital biology, potentially unlocking novel molecules that traditional methods might overlook (source: @IsomorphicLabs, https://x.com/IsomorphicLabs/status/2013583586784387193).